Therapeutics

Developing Next Generation Therapeutics for Healthy Life

Pipeline
Oncology/Immuno-Oncology
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

Porustobart HBM4003

CTLA-4

Melanoma, HCC*, RCC* & Other Advanced Solid Tumors

Melanoma, HCC*, NEC/NET* & Other Advanced Solid Tumors

NSCLC* & Other Advanced Solid Tumors

Global

Global

Global

view more

HBM7008

B7H4x4-1BB

Solid Tumors

Global

HBM7022

CLDN18.2xCD3

Solid Tumors

Global License to AstraZeneca

HBM1022

CCR8

Solid Tumors

Global

HBM1020

B7H7

Solid Tumors

Global

HBM1007

CD73

Solid Tumors

Global

HBM9033

MSLN ADC

Solid Tumors

Global

HBM9027

PD-L1xCD40

Solid Tumors

Global

HBM1047

CD200R1

Solid Tumors

Global

HBM7004

B7H4×CD3

Solid Tumors

Global

Immunology
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
view more

Batoclimab HBM9161(HanAll)

FcRn

MG*

TED*

Greater China License to CSPC

Greater China License to CSPC

HBM9378

TSLP

Asthma

Global

HBM9022(AbbVie; Utrecht University; Erasmus MC)

SARS-COV-2

COVID-19

Global License to AbbVie

  • HBM

  • Partner

  • Registrational Clinical Trial

  • Monotherapy

  • PD1 / Chemo

  • Breakthrough Therapy Designation

* HCC = Hepatocellular Carcinoma

* RCC = Renal Cell Carcinoma

* NEC = Neuroendocrine Carcinoma

* NET = Neuroendocrine Tumour

* NSCLC = Non-Small Cell Lung Cancer

* MG = Myasthenia Gravis

* TED = Thyroid Eye Disease

Publications